
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca is attractive because its lead pan-RAS asset, ERAS-0015, is showing increasingly credible efficacy across PDAC and NSCLC while maintaining relatively clean tolerability, including a 57% uORR in seven evaluable 2L+ KRAS G12X PDAC patients and a 60% uORR in the U.S. lung dataset. The company also has multiple near-term catalysts, with first ERAS-4001 clinical data expected in 2H26 and potentially registration-enabling studies for ERAS-0015 planned for 2027, which broadens the upside beyond a single program. Financially, 2Q26 net loss was $44.1M, cash, cash equivalents, and marketable securities were $384.3M at quarter-end, and the July 2026 public offering added $632.5M in gross proceeds, strengthening the balance sheet to fund the outlined milestones.
Bears say
Erasca is a clinical-stage company with no approved products, so its valuation depends heavily on a small RAS/MAPK-focused pipeline that remains exposed to clinical, regulatory, and commercial setbacks. Its lead assets, ERAS-0015 and ERAS-4001, are still in development, and the discovery-stage ERAS-12 adds further uncertainty rather than near-term diversification. The negative outlook is reinforced by the explicit risk of new competitors, lower-than-expected product sales, intellectual property challenges, management execution issues, and possible M&A missteps, all of which could undermine shareholder value.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Erasca Inc (ERAS) Forecast
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares